Abstract
New research on Oncology -Lung Cancer is the subject of a report. According to news reporting originating in Guangzho u, People's Republic of China, by NewsRx journalists, research stated, "An incre asing number of early-stage lung adenocarcinoma (LUAD) are detected as lung nodu les. The radiological features related to LUAD progression remain further invest igation." The news reporters obtained a quote from the research from the South China Unive rsity of Technology, "Exploration is required to bridge the gap between radiomic s features and molecular characteristics of lung nodules. Consensus clustering w as applied to the radiomics features of 1,212 patients to establish stable clust ering. Clusters were illustrated using clinicopathological and next-generation s equencing (NGS). A classifier was constructed to further investigate the molecul ar characteristic in patients with paired CT and RNA-seq data. Patients were clu stered into 4 clusters. Cluster 1 was associated with a low consolidation-to-tum or ratio (CTR), pre-invasion, grade I disease and good prognosis. Clusters 2 and 3 showed increasing malignancy with higher CTR, higher pathological grade and p oor prognosis. Cluster 2 possessed more spread through air spaces (STAS) and clu ster 3 showed higher proportion of pleural invasion. Cluster 4 had similar clini copathological features with cluster 1 except higher proportion of grade II dise ase. RNA-seq indicated that cluster 1 represented nodules with indolent growth a nd good differentiation, whereas cluster 4 showed progression in cell developmen t but still had low proliferative activity. Nodules with high proliferation were classified into clusters 2 and 3. Additionally, the radiomics classifier distin guished cluster 2 as nodules harboring an activated immune environment, while cl uster 3 represented nodules with a suppressive immune environment. Furthermore, gene signatures associated with the prognosis of early-stage LUAD were validated in external datasets. Radiomics features can manifest molecular events driving progression of lung adenocarcinoma."
NETL
NSTL